Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:midostaurin
|
| gptkbp:approvalYear |
2017
|
| gptkbp:ATCCode |
L01EX10
|
| gptkbp:brand |
gptkb:Rydapt
|
| gptkbp:CASNumber |
gptkb:120685-11-2
|
| gptkbp:chemicalFormula |
C35H30N4O4
|
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:midostaurin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rydapt
|
| gptkbp:indication |
gptkb:systemic_mastocytosis
gptkb:acute_myeloid_leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
FLT3 inhibitor
multikinase inhibitor |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea headache rash upper respiratory tract infection febrile neutropenia |
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|